ClinicalTrials.gg
CompletedNCT02695940Updated Feb 24, 2025

Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis

A Phase 2 interventional study of LEO 124249 ointment 30 mg/g and LEO 124249 ointment vehicle in Inverse Psoriasis, sponsored by LEO Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 79 studies in Psoriasis by LEO Pharma — 1 open to participants now, 2 under way, none of them phase 3. Psoriasis · LEO Pharma.

Enrollment
35th of 71
69 · median 63
Started
2016
with 7 others
Phase 2
24 of 79
1 open now
Registered
59th of 79
by date

Among the 79 studies in Psoriasis by LEO Pharma, this one is the 35th largest by enrollment of the 71 interventional ones that give a count, is one of 8 that started in 2016, is one of 24 in phase 2, and was the 59th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 79 studies in Psoriasis by LEO Pharma is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Psoriasis by LEO Pharma, or all of them as a file.
02

Study summary

This is a phase 2a trial testing twice daily administration of LEO 124249 ointment 30 mg/g in the treatment of mild to moderate inverse psoriasis. Patients will be treated for 6 weeks, and the efficacy and safety will be compared with the treatment of LEO 124249 ointment vehicle.

Read the detailed description

Single country, Multi-center, prospective, randomised, double-blind, 2 arms parallel-group, vehicle-controlled, 6 weeks, phase 2a trial in subjects with mild to moderate inverse psoriasis. LEO 124249 ointment 30 mg/g and LEO 124249 ointment vehicle treatments will be compared with regards to efficacy and safety.

03

Conditions studied

  • Inverse Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated prior to any trial specific procedures
  • Male or female subjects between 18 to 75 years
  • A diagnosis of stable mild to moderate inverse psoriasis (i.e. axillae, the infra- and intermammary, genital, scrotum, abdominal and retroauricular folds; the intergluteal cleft and perianal skin, in addition to neck or other skin folds). Mild to moderate is defined as having at least score 1 for each individual sign thickness and redness, and total TSS score of at least 5.
  • The total treatment area can be up to 4% BSA (720 cm2).
  • Subjects must have a history of psoriasis, or have psoriasis, or present with characteristic psoriasis leasons elsewhere on the body (including the scalp) at Visit 1 (Screening)
  • Stable inverse psoriasis based on TSS evaluated at Visit 1 (Screening) and at Visit 2 (Start of treatment), which must not differ more than 1 point in any single clinical sign score (redness, scaling and thickness)
  • Except for inverse psoriasis, overall good health including well controlled diseases (e.g. hypertension, diabetes, and thyroid disease) as determined by medical history, physical examination, (ECG), vital signs (blood pressure, heart rate and body temperature) and clinical laboratory evaluation

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are breastfeeding or pregnant
  • Severe chronic inverse psoriasis, or psoriasis on the body (>30% of BSA)
  • Current diagnosis of acute guttate, erythrodermic, exfoliative or pustular psoriasis
  • Signs of viral (e.g. herpes or varicella) lesions of the skin, or signs of clinically active fungal or bacterial infection in any of the inverse psoriasis areas, as judged by the investigator
  • Use of biological therapies (marketed/not marketed) with a possible effect on inverse psoriasis within 4 weeks (etanercept), 8 weeks (adalimumab, alefacept, infliximab), 16 weeks (ustekinumab, secukinumab) or 4 weeks/5 half-lives (whichever is longer) for experimental biological products prior to Visit 2 (Start of treatment)
  • Use of systemic treatments (marketed/non-marketed), other than biologics, with a potential effect on inverse psoriasis (e.g., , retinoids, dimethylfumarate, cyclosporine, azathioprine methotrexate, ) within 6 weeks prior to Visit 2 (Start of treatment) (inhaled or intranasal steroids corresponding of up to 1 mg prednisone for asthma or rhinitis may be used)
  • Use of very potent topical corticosteroids (WHO group IV) for the treatment of psoriasis on the body and/or scalp within 4 weeks prior to Visit 2 (Start of treatment)
  • Use of topical medication for the treatment of inverse psoriasis: WHO group I-III corticosteroids, retinoids, vitamin D analogues, immunomodulators (e.g. macrolides, calcineurin), anthracen derivatives, tar, or salicylic acid within 2 weeks prior to Visit 2 (Start of treatment)
  • Exposure to phototherapy (PUVA, UVA, UVB, Grenz Ray therapy) within 4 weeks prior to Visit 2 (Start of treatment)
  • Subjects with a positive score antibody, HBsAg, anti- or anti- test at Visit 1 (Screening)
  • Subjects with history of an immunocompromising disease (e.g., lymphoma, HIV, Wiskott-Aldrich Syndrome)
  • Any current dermatological disorder (e.g. serborrhic dermatitis, contact dermatitis, cutaneous mycosis) which may confound the evaluation of inverse psoriasis
  • Known (other than cervical carcinoma in situ, basal cell or squamous cell carcinoma) within 5 years before Visit 1 (Screening)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Active comparator
    LEO 124249 ointment 30 mg/g

    Drug LEO 124249 ointment 30 mg/g twice daily application for 6 weeks, maximum of 1.44 g ointment per day

    Drug: LEO 124249 ointment 30 mg/g

  • Placebo comparator
    LEO 124249 ointment vehicle

    LEO 124249 ointment vehicle twice daily application for 6 weeks, maximum of 1.44 g ointment per day

    Other: LEO 124249 ointment vehicle

Interventions

  • DrugLEO 124249 ointment 30 mg/g

    Drug page: Delgocitinib

  • OtherLEO 124249 ointment vehicle
06

What researchers measure

Primary outcomes

  1. The total sign score (TSS) at Week 6 (Visit 6)

    Time frame: after 6 weeks of treatment

Secondary outcomes

  1. For PGA, the number of subjects reaching controlled disease at Visit 6 (Week 6)

    Time frame: after 6 weeks of treatment

  2. Score for clinical sign redness for inverse psoriasis: (score 0 to 4) at Visit 6 (Week 6)

    Time frame: after 6 weeks of treatment

  3. Score for clinical sign thickness for inverse psoriasis: (score 0 to 4) at Visit 6 (Week 6)

    Time frame: after 6 weeks of treatment

  4. Score for clinical sign scaliness for inverse psoriasis: (score 0 to 4) at Visit 6 (Week 6)

    Time frame: after 6 weeks of treatment

  5. Size of treatment area of inverse psoriasis at Visit 6 (Week 6)

    Time frame: after 6 weeks of treatment

  6. For PaGA, the number of subjects reaching controlled disease at Visit 6 (Week 6)

    Time frame: after 6 weeks of treatment

  7. Dermatology Life Quality Index (DLQI) questionnaire at Visit 6 (Week 6)

    Time frame: after 6 weeks of treatment

  8. Treatment satisfaction questionnaire for medication (TSQM II) at Visit 6 (Week 6)

    Time frame: after 6 weeks of treatment

  9. Subjects assessment of itching (daily assessment in diary of the first 14 days on treatment (between Visits 2 (Start of treatment) to 4 (Week 2), followed by assessments at the following Visits 4 (Week 2) to 6 (Week 6))

    Time frame: after 6 weeks of treatment

  10. Subjects overall assessment of cosmetic acceptability at Visit 6 (Week 6)

    Time frame: after 6 weeks of treatment

  11. Evaluation of population steady state pharmacokinetics of LEO 124249 at Visit 3 (Week 1), by sampling of 1 blood sample to get 1 plasma concentration value per patient after 1 weeks treatment

    Time frame: after 6 weeks of treatment

  12. Adverse Events

    Time frame: after 6 weeks of treatment

  13. Abnormal and clinically significant findings in blood pressure, heart rate, body temperature will be listed

    Time frame: after 6 weeks of treatment

  14. Abnormal and clinically significant laboratory parameters will be listed

    Time frame: after 6 weeks of treatment

07

Study locations

1 site
  • Johannes Niesmann
    Bochum, 44803, Germany
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2016
First posted
Mar 2, 2016
Start
Mar 2016
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02695940
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Mar 2, 2016
Start date
Mar 2016
Primary completion
Sep 2016
Completion
Sep 2016
Last update
Feb 24, 2025

Study contacts

Thomas Luger, MD
principal investigator · Universitätsklinikum Münster, Klinik fur Hautkrankheiten

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion